Clinical trials: Essential (Primary) Hypertension
Hypertension, Essential (Primary) Hypertension
Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension
Yufeng Ningxin, a traditional Chinese medicine, has demonstrated potential antihypertensive effects in animal studies and small clinical trials, but has not yet been rigorously evaluated in large randomized clinical trials.
- Trial name
- NCT07607275
- Testing
- Yufeng Ningxin tablets
- Where
- 16 sites in China
- Volunteers
- 350 people
- Sponsor
- Beijing Anzhen Hospital
Primary Hypertension
Effect of Aerobic EXercise on MiCroVAscular RarefacTION in Chinese Mild HyperteNsive Patients（EXCAVATION-CHN1）
The purpose of this study is to determine the effect of aerobic exercise training on microcirculation rarefaction in Chinese young male primary hypertensive patients stage 1.
- Trial name
- NCT02817204
- Testing
- Aerobic Exercise, Health Education
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hypertension
Salt Intake and Blood Pressure Control in Adults With Essential Hypertension
The goal of this study is to explore the barriers and facilitators to adopting a reduced dietary salt and increased potassium intake among adults with essential hypertension in Singapore, and to evaluate the feasibility and…
- Trial name
- NCT07025928
- Testing
- Decreased Salt High Potassium Tool (DSHP Tool)
- Where
- Singapore
- Volunteers
- 190 people
- Sponsor
- Sun Jingfeng
Primary Hypertension
A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.
- Trial name
- NCT06884085
- Testing
- Co-administration of AD-227A and AD-227B, Administration of AD-227
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Hypertension, Congestive Heart Failure
To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
To compare and evaluate the efficacy and safety of Candemore tab. versus Atacand tab. on blood pressure in patients with hypertension diagnosed congestive heart failure
- Trial name
- CANTABILE (NCT01682564)
- Testing
- Candemore tablet, Atacand tablet
- Where
- 14 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension, Essential, Primary Hypercholesterolemia
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
The purpose of this study is to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
- Trial name
- NCT06448962
- Testing
- AD-2021, AD-2022
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- Addpharma Inc.
Hypertension, Left Ventricular Diastolic Dysfunction
Sacubitril/Valsartan Versus Valsartan Alone on Left Atrial Volume Index in Hypertensive Patients
Hypertension is a leading global risk factor for cardiovascular disease and is frequently associated with left atrial and ventricular remodeling, leading to subclinical diastolic dysfunction[cite: 2].
- Conditions
- Hypertension, Left Ventricular Diastolic Dysfunction, Essential (Primary) Hypertension
- Trial name
- NCT07853625
- Testing
- Sacubitril / Valsartan, Valsartan
- Volunteers
- 102 people
- Sponsor
- University of Health Sciences Lahore
Cardiovascular Disease, Essential Hypertension
The Northwest Coalition for Primary Care Practice Support
The purpose of this project is to build capacity for quality improvement (QI) in small primary care practices across Washington, Oregon and Idaho by improving risk factors for heart attacks such as blood pressure, cholesterol and…
- Conditions
- Cardiovascular Disease, Essential Hypertension, Nicotine Dependence, Hyperlipidemia
- Trial name
- H2N (NCT02839382)
- Testing
- Coaching, Educational Outreach, Site Visits
- Where
- United States
- Volunteers
- 209 people
- Sponsor
- Kaiser Permanente
Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure
Positive Care Effect of the Digital Health Assistant ADELE Blood Pressure for Hypertension Patients
High blood pressure (hypertension) can cause damage to vital organs such as the heart, kidneys, eyes, brain and blood vessels. The risk of developing high blood pressure increases with age.
- Conditions
- Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure, Hypertensive Heart Disease Without (Congestive) Heart Failure, Other Secondary Hypertension
- Trial name
- A0007 (NCT06663280)
- Testing
- Digital health assistant ADELE
- Where
- 2 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Alma Phil Gmbh
PRIMARY HYPERTENSION
The Effect of Self-Acupressure on Blood Pressure, Stress, and Well-Being Levels in Individuals With Hypertension
This randomized controlled trial examines the effects of nurse-led self-acupressure at HT7, LI4, PC6, and EX3 points on blood pressure, stress, and well-being in adults with primary hypertension.
- Trial name
- SAPH (NCT07577973)
- Testing
- Real Acupressure, Usual Care
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Abant Izzet Baysal University
Primary Hypertension
Nijmegen Antihypertensive Management Improvement Study
High blood pressure is an important risk factor for diseases of heart and blood vessels like myocardial infarction and stroke. Many patients are not treated to target blood pressures, even though good blood pressure lowering…
- Trial name
- NAMIS (NCT00457483)
- Testing
- hydrochlorothiazide, valsartan, 80 mg once-a-day
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- Radboud University Medical Center
Primary Hypertension
Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India
Hypertension is a leading cause of morbidity and mortality globally. Although multiple drugs are frequently used to treat it, in the South Asian context, evidence is lacking on best drug combinations.
- Trial name
- TOPSPIN (NCT05683301)
- Testing
- Amlodipine + Perindopril, Perindopril + Indapamide, Amlodipine + Indapamide
- Where
- 35 sites in India
- Volunteers
- 1,981 people
- Sponsor
- Centre for Chronic Disease Control, India
Primary Hypertension
Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting
One of the most common adverse effects resulting from the therapy with thiazides, thiazide-like diuretics and loop diuretics is increased potassium secretion.
- Trial name
- POTASSIUM (NCT01392534)
- Testing
- Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)
- Where
- Poland
- Volunteers
- 1,586 people
- Sponsor
- Bayer
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension…
- Trial name
- NCT05930028
- Testing
- Fimasartan, Ezetimibe/Atorvastatin
- Where
- South Korea
- Volunteers
- 148 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
This double-blind 8 week study will evaluate dose response, efficacy (blood pressure lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at low, mid and high weight-based doses.
- Trial name
- NCT01150357
- Testing
- Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Primary Hypertension
Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease
The Renin-Angiotensin-Aldosterone-system is important in the development of cardiovascular organ damage caused by arterial hypertension.
- Trial name
- NCT00865501
- Testing
- spironolactone
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Primary Hypertension
A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components
This is a randomised, open-label; parallel group, multicentric study comparing the efficacy and safety of fixed-dose-combinations of Metoprolol XL plus Amlodipine with individual components of the combination.
- Trial name
- MARS (NCT00819104)
- Testing
- Metoprolol XL 50mg + Amlodipine 5mg, Metoprolol XL 25 mg + Amlodipine 2.5mg, Metoprolol XL 50mg
- Where
- 11 sites in India
- Volunteers
- 402 people
- Sponsor
- AstraZeneca
Primary Hypertension, Obesity
The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.
Despite the available means of treating primary arterial hypertension, the prevalence of hypertensive patients with inadequately controlled blood pressure levels, remains high.
- Trial name
- NCT06208072
- Testing
- Irbesartan 150mg, Eplerenone 25 mg
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Hippocration General Hospital
Primary Hypertension
China Stroke Primary Prevention Trial
The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.
- Trial name
- CSPPT (NCT00794885)
- Testing
- Enalapril/folic acid, Enalapril maleate
- Where
- 2 sites in China
- Volunteers
- 20,702 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Essential Arterial Hypertension
Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension
This is a phase III, non-inferiority, randomized, double-blind, double-dummy, active-controlled, multicenter study to compare the efficacy and safety of N0877 versus double combination with already established efficacy on…
- Trial name
- ATHESA (NCT06608472)
- Testing
- N0877, Benicar HCT ® Tablets 40 mg/25 mg
- Sponsor
- Eurofarma Laboratorios S.A.